Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

Article Type

Case Report

Published

The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.

Read more

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Article Type

Case Report

Published

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.